Axcelis Secures Order from Major Asian Memory Manufacturer for Optima Hd Imax
Customer's Commitment to Optima Technology Strengthens with Addition of New Molecular Implanter
BEVERLY, Mass.--(BUSINESS WIRE)--Jan. 4, 2007--Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced that it received an order in December 2006 from one of the world's top memory manufacturers for its Optima HD Imax(TM) molecular implanter. Following on the customer's previous order last year for Axcelis' standard Optima HD high dose implanter, the new Optima HD Imax will enable them to dramatically increase productivity by implanting clusters of boron rather than individual atoms. The tool was selected specifically for its ability to perform high dose, dual poly gate implants and other advanced applications on leading edge DRAM devices. The system is expected to ship this month.
"This order is very significant, serving as powerful validation for our Optima HD platform while demonstrating customer confidence in this groundbreaking molecular implanter," said Mary Puma, chairman and CEO of Axcelis. "The Optima HD Imax provides the most effective throughput because it delivers the highest beam current performance at the lowest energy with zero contamination. This convincing productivity advantage, built on standard implant technology, sets the Optima HD Imax apart from competing technologies."
The Optima HD Imax implants molecules of B18H22, which includes 18 boron atoms, resulting in higher productivity than users can achieve with traditional approaches that implant one atom at a time. It delivers precise implants using Axcelis' advanced spot beam technology, resulting in exceptional implant uniformity and repeatability, while avoiding the risk of energy contamination associated with beam deceleration. The resulting boost in productivity enables chipmakers to adopt a number of emerging trends, including dual poly gate applications for advanced memory devices and shallower junctions in logic chips.
About Axcelis Technologies, Inc.
Axcelis Technologies, Inc., headquartered in Beverly, Massachusetts, provides innovative, high-productivity solutions for the semiconductor industry. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation, rapid thermal processing, and cleaning and curing systems. Axcelis Technologies also licenses its 50% owned joint venture, SEN Corporation, an SHI and Axcelis Company, to manufacture and sell certain implant products in Japan. The company's Internet address is: www.axcelis.com
Forward Looking Statements
This document contains forward-looking statements under the SEC safe harbor provisions. These statements are based on management's current expectations and should be viewed with caution. They are subject to various risks and uncertainties, many of which are outside the control of the Company, including the timing of orders and shipments, the conversion of orders to revenue in any particular quarter, or at all, our ability to implement successfully our profit plans, the continuing demand for semiconductor equipment, relative market growth, continuity of business relationships with and purchases by major customers, competitive pressure on sales and pricing, increases in material and other production costs that cannot be recouped in product pricing and global economic, political and financial conditions. These risks and other risk factors relating to Axcelis are described more fully in the most recent Form 10-K filed by Axcelis and in other documents filed from time to time with the Securities and Exchange Commission.
CONTACT: Company Contact: Axcelis Technologies, Inc. David Snyder, +1-978-787-4273 Fax: +1-978-787-4275 david.snyder@axcelis.com or Investor Contact: Axcelis Technologies, Inc. Steve Bassett, +1-978-787-4000 Fax: +1-978-787-9133 investor.relations@axcelis.com or Agency Contact: Loomis Group Heather Smith, +1-617-638-0022 Fax: +1-617-638-0033 smithh@loomisgroup.com SOURCE: Axcelis Technologies, Inc.
